secwatch.observer — SEC 8-K summary
======================================

Issuer:     Werewolf Therapeutics, Inc. (HOWL)
CIK:        0001785530
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001785530-23-000016
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Werewolf Therapeutics Q1 net loss $12.0M; COO retiring; WTX-124 data expected 4Q23
--------------------------------------------------------------------------------

- Net loss of $12.0M improved from $15.3M in Q1 2022; cash and equivalents $147.9M.
- Collaboration revenue of $4.5M from Jazz Pharma licensing agreement; R&D spend $11.7M.
- COO Reid Leonard retiring effective June 30, 2023; founding executive team member.
- Phase 1/1b WTX-124 monotherapy data (safety, tolerability, efficacy) expected 4Q 2023.
- New candidate WTX-712 (IL-21 INDUKINE) preclinical data presented at AACR 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/0001785530-23-000016-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785530/000178553023000016/howl-20230511.htm
  HTML page:      https://secwatch.observer/filing/0001785530-23-000016

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer